Skip to main navigation Skip to search Skip to main content

Toxoplasma gondii HLA-B*0702-restricted GRA7 20-28 peptide with adjuvants and a universal helper T cell epitope elicits CD8 + T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 mice

  • Hua Cong
  • , Ernest J. Mui
  • , William H. Witola
  • , John Sidney
  • , Jeff Alexander
  • , Alessandro Sette
  • , Ajesh Maewal
  • , Kamal El Bissati
  • , Ying Zhou
  • , Yasuhiro Suzuki
  • , Daniel Lee
  • , Stuart Woods
  • , Caroline Sommerville
  • , Fiona L. Henriquez
  • , Craig W. Roberts
  • , Rima McLeod

Research output: Contribution to journalArticlepeer-review

40 Scopus citations

Abstract

The ability of CD8 + T cells to act as cytolytic effectors and produce interferon-γ (IFN-γ) was demonstrated to mediate resistance to Toxoplasma gondii in murine models because of the recognition of peptides restricted by murine major histocompatibility complex (MHC) class I molecules. However, no T gondii-specific HLA-B07-restricted peptides were proven protective against T gondii. Recently, 2 T gondii-specific HLA-B*0702-restricted T cell epitopes, GRA7 20-28 (LPQFATAAT) and GRA3 27-35 (VPFVVFLVA), displayed high-affinity binding to HLA-B*0702 and elicited IFN-γ from peripheral blood mononuclear cells of seropositive HLA-B*07 persons. Herein, these peptides were evaluated to determine whether they could elicit IFN-γ in splenocytes of HLA-B*0702 transgenic mice when administered with adjuvants and protect against subsequent challenge. Peptide-specific IFN-γ-producing T cells were identified by enzyme-linked immunosorbent spot and proliferation assays utilizing splenic T lymphocytes from human lymphocyte antigen (HLA) transgenic mice. When HLA-B*0702 mice were immunized with one of the identified epitopes, GRA7 20-28 in conjunction with a universal CD4 + T cell epitope (PADRE) and adjuvants (CD4 + T cell adjuvant, GLA-SE, and TLR2 stimulatory Pam 2Cys for CD8 + T cells), this immunization induced CD8 + T cells to produce IFN-γ and protected mice against high parasite burden when challenged with T gondii. This work demonstrates the feasibility of bioinformatics followed by an empiric approach based on HLA binding to test this biologic activity for identifying protective HLA-B*0702-restricted T gondii peptides and adjuvants that elicit protective immune responses in HLA-B*0702 mice.

Original languageEnglish
Pages (from-to)1-10
Number of pages10
JournalHuman Immunology
Volume73
Issue number1
DOIs
StatePublished - Jan 2012

Bibliographical note

Funding Information:
Funding provided through NIH NIAID U01AI77887 , and a grant from the National Natural Science Foundation Project of China (No. 81171604 ).

Funding

Funding provided through NIH NIAID U01AI77887 , and a grant from the National Natural Science Foundation Project of China (No. 81171604 ).

FundersFunder number
NIH-NIAIDU01AI77887
National Institute of Allergy and Infectious DiseasesR01AI027530
Innovative Research Group Project of the National Natural Science Foundation of China81171604

    UN SDGs

    This output contributes to the following UN Sustainable Development Goals (SDGs)

    1. SDG 3 - Good Health and Well-being
      SDG 3 Good Health and Well-being

    Keywords

    • Adjuvant
    • HLA-B07 epitopes
    • PADRE
    • Toxoplasma gondii
    • Vaccine

    ASJC Scopus subject areas

    • Immunology and Allergy
    • Immunology

    Fingerprint

    Dive into the research topics of 'Toxoplasma gondii HLA-B*0702-restricted GRA7 20-28 peptide with adjuvants and a universal helper T cell epitope elicits CD8 + T cells producing interferon-γ and reduces parasite burden in HLA-B*0702 mice'. Together they form a unique fingerprint.

    Cite this